J. A. R. Mead

1.2k total citations
51 papers, 953 citations indexed

About

J. A. R. Mead is a scholar working on Molecular Biology, Rheumatology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, J. A. R. Mead has authored 51 papers receiving a total of 953 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 11 papers in Rheumatology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in J. A. R. Mead's work include Folate and B Vitamins Research (11 papers), Biochemical and Molecular Research (6 papers) and Acute Lymphoblastic Leukemia research (6 papers). J. A. R. Mead is often cited by papers focused on Folate and B Vitamins Research (11 papers), Biochemical and Molecular Research (6 papers) and Acute Lymphoblastic Leukemia research (6 papers). J. A. R. Mead collaborates with scholars based in United States, United Kingdom and Malaysia. J. A. R. Mead's co-authors include J. N. Smith, R. T. Williams, Kenneth F. Finger, Anthony W. Schrecker, L.C. Mishra, John M. Venditti, Manford C. Castle, Robert Tomchick, William A. Creasey and A Goldin and has published in prestigious journals such as Nature, The Lancet and Analytical Biochemistry.

In The Last Decade

J. A. R. Mead

47 papers receiving 820 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. A. R. Mead United States 15 407 163 151 97 78 51 953
T. Nagasaki Japan 11 502 1.2× 129 0.8× 162 1.1× 37 0.4× 145 1.9× 28 1.3k
D.R. Grassetti United States 14 735 1.8× 114 0.7× 164 1.1× 44 0.5× 150 1.9× 21 1.4k
J.B. Jepson United Kingdom 13 518 1.3× 76 0.5× 102 0.7× 136 1.4× 148 1.9× 30 1.4k
Mario Pinza Italy 22 426 1.0× 198 1.2× 280 1.9× 118 1.2× 94 1.2× 69 1.4k
Joseph Jarabak United States 23 584 1.4× 84 0.5× 111 0.7× 112 1.2× 140 1.8× 46 1.4k
P.M. Woollard United Kingdom 19 403 1.0× 114 0.7× 276 1.8× 88 0.9× 169 2.2× 25 1.2k
Wendell H. Rooks Poland 12 213 0.5× 72 0.4× 233 1.5× 115 1.2× 151 1.9× 33 912
Earl G. Burton United States 16 339 0.8× 127 0.8× 217 1.4× 125 1.3× 50 0.6× 26 956
Lawrence M. Pinkus United States 18 552 1.4× 107 0.7× 67 0.4× 52 0.5× 164 2.1× 24 1.1k
Teruyuki Kawabata Japan 19 430 1.1× 226 1.4× 83 0.5× 71 0.7× 65 0.8× 35 1.2k

Countries citing papers authored by J. A. R. Mead

Since Specialization
Citations

This map shows the geographic impact of J. A. R. Mead's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. A. R. Mead with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. A. R. Mead more than expected).

Fields of papers citing papers by J. A. R. Mead

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. A. R. Mead. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. A. R. Mead. The network helps show where J. A. R. Mead may publish in the future.

Co-authorship network of co-authors of J. A. R. Mead

This figure shows the co-authorship network connecting the top 25 collaborators of J. A. R. Mead. A scholar is included among the top collaborators of J. A. R. Mead based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. A. R. Mead. J. A. R. Mead is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Siegel, Christopher, J. A. R. Mead, Joseph F. Buell, et al.. (1999). COMPARISON OF DACLIZUMAB VS. ATGAM INDUCTION IN KIDNEY PANCREAS TRANSPLANTATION. Transplantation. 67(7). S223–S223. 2 indexed citations
2.
Loss, G., Hani P. Grewal, Christopher Siegel, et al.. (1998). Reversal of Delayed Hyperacute Renal Allograft Rejection With a Tacrolimus-Based Therapeutic Regimen. Transplantation Proceedings. 30(4). 1249–1250. 7 indexed citations
3.
Castle, Manford C. & J. A. R. Mead. (1978). Investigations of the metabolic fate of tritiated vincristine in the rat by high-pressure liquid chromatography. Biochemical Pharmacology. 27(1). 37–44. 31 indexed citations
4.
Chinn, R. H., Rosalind Maskell, J. A. R. Mead, & Annemarie Polak. (1976). Renal stones and urinary infection: a study of antibiotic treatment.. BMJ. 2(6049). 1411–1413. 24 indexed citations
5.
Waravdekar, V.S., et al.. (1974). The disposition of the antitumor agent, sangivamycin, in mice.. PubMed. 34(5). 1005–9. 17 indexed citations
6.
Mishra, L.C., et al.. (1974). Reduction and metabolism of dihydrohomofolate in rhesus monkeys.. PubMed. 34(12). 3187–91. 1 indexed citations
7.
Mishra, L.C. & J. A. R. Mead. (1973). Physiological disposition of 1-acetyl-2-picolinoylhydrazine (NSC68626) in rats bearing Walker carcinosarcoma 256.. PubMed. 33(10). 2393–7. 1 indexed citations
8.
Mishra, L.C., et al.. (1972). A method for assessing dihydrofolate reductase inhibition in vivo. Analytical Biochemistry. 48(2). 515–523. 5 indexed citations
9.
DeConti, Ronald C., Robert Tomchick, J. A. R. Mead, et al.. (1972). Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone.. PubMed. 32(7). 1455–62. 99 indexed citations
10.
Mishra, L.C., et al.. (1972). Chemical transformations of tetrahydrohomofolic acid in vitro and in vivo. Chemico-Biological Interactions. 4(2). 97–102. 3 indexed citations
11.
Mishra, L.C., et al.. (1971). Effect of pretreatment with methotrexate on the reduction of dihydrohomofolic acid in mice. Biochemical Pharmacology. 20(10). 2871–2878. 6 indexed citations
12.
Tomchick, Robert & J. A. R. Mead. (1970). A method for the determination of 5-hydroxypyridine-2-carboxaldehyde thiosemicarbazone (NSC-107,392) in biological material. Biochemical Medicine. 4(1). 13–23. 2 indexed citations
13.
Auletta, Angela E., J. A. R. Mead, & V.S. Waravdekar. (1970). The effect of folate and homofolate on dihydrofolate reductase levels in mouse kidney. Abstr.. The Mouseion at the JAXlibrary (Jackson Laboratory). 610. 1 indexed citations
14.
Canellos, George P., J. A. R. Mead, Nathaniel H. Greenberg, & Anthony W. Schrecker. (1967). The effect of treatment with cytotoxic agents on mouse spleen dihydrofolate reductase activity.. PubMed. 27(4). 784–8. 3 indexed citations
15.
Kline, I, et al.. (1966). The antileukemic effectiveness of 5-fluorouracil and methotrexate in the combination chemotherapy of advanced leukemia L1210 in mice.. PubMed. 26(5). 848–52. 25 indexed citations
16.
Mead, J. A. R., A Goldin, Roy L. Kisliuk, et al.. (1966). Pharmacologic aspects of homofolate derivatives in relation to amethopterin-resistant murine leukemia.. PubMed. 26(11). 2374–9. 20 indexed citations
17.
Mead, J. A. R., et al.. (1964). Experiments on determination of melphalan by fluorescence. Interaction with protein and various solutions. Analytical Biochemistry. 7(3). 259–268. 23 indexed citations
18.
Condit, Paul T. & J. A. R. Mead. (1963). Further observations on the site of action of amethopterin. Biochemical Pharmacology. 12(1). 94–96. 5 indexed citations
19.
Venditti, John M., Anthony W. Schrecker, J. A. R. Mead, I Kline, & Abraham Goldin. (1960). Influence of the route of administration on the relative effectiveness of 3',5'-dichloroamethopterin and amethopterin against advanced leukemia (L1210) in mice.. PubMed. 20. 1451–6. 6 indexed citations
20.
Schrecker, Anthony W., et al.. (1960). Effect of orally administered 3', 5'-dichloroamethopterin on formate-C14 incorporation in leukemic mice.. PubMed. 20. 1457–61. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026